Who Paid My Doc Search
Menu
Organisation paid for research Program year 2022 Source: CMS Open Payments

CroNOLA LLC

Neither a doctor nor a teaching hospital

Research payments

$219,207

76 payments

Through program year 2022, CroNOLA LLC is reported as receiving $219,207 in research payments, across 76 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $592 1
2021 Research $1,766 5
2020 Research $92,269 39
2019 Research $124,580 31

Breakdown

Who paid Research payments · program years 2019–2022
  1. Allergan Inc. $73,030 35 payments
  2. Janssen Research & Development, LLC $57,210 10 payments
  3. Roche Products Limited $40,400 4 payments
  4. Genentech, Inc. $31,250 3 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $8,527 4 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $3,211 5 payments
  7. Pfizer Inc. $2,800 3 payments
  8. Boehringer Ingelheim RCV GmbH & Co KG $2,102 9 payments
  9. Arena Pharmaceuticals, Inc. $592 1 payment
  10. Ironwood Pharmaceuticals, Inc $84 2 payments
Studies the money was for Research payments · program years 2019–2022
  1. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $23,377 8 payments
  2. A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease $22,348 7 payments
  3. Crohn S Disease Program Cohort 1 Induction Cohort II Maintenance $20,200 2 payments
  4. Crohn S Disease Program Ole $20,200 2 payments
  5. A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Platform Study Evaluating the Efficacy and Safety of Interventions in Participants with Moderately to Severely Active Crohn's Disease $17,862 2 payments
  6. Ada H2h Indxn 1 $17,750 2 payments
  7. A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis $17,000 1 payment
  8. A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis $16,166 10 payments
  9. Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) $15,488 9 payments
  10. 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis $13,984 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record